Biodesix announces CMS designates Nodify CDT test as ADLT effective June 30

Biodesix announced that the Centers for Medicare & Medicaid Services CMS has designated the Nodify CDT Test as an Advanced Diagnostic Laboratory Test or ADLT, effective June 30. Obtaining ADLT status is a recognition that the Nodify CDT test meets the stringent criteria established under the Protecting Access to Medicare Act of 2014 . ADLT status is reserved for innovative tests with Medicare coverage that provide new clinical diagnostic information that cannot be obtained from any other test or combination of tests. The payment amount for the Nodify CDT test as established by the Medicare Administrative Contractor is $649. “Receiving ADLT status is a major milestone for Biodesix and confirms the clinical value and unique nature of the Nodify CDT test,” says Scott Hutton, President and CEO of Biodesix. “We are committed to working closely with CMS and commercial payers to ensure that patients and physicians have access to all tests in the Biodesix portfolio that aid in the diagnosis and treatment of lung cancer.”